No Data
No Data
Express News | NextCure Announces Acceptance of Ind Application for Lncb74
NextCure Announces Acceptance of IND Application for LNCB74
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure, Inc. Reports Promising Preclinical Data for NC605 in Osteogenesis Imperfecta Treatment
Express News | NextCure Highlights Presentation Of Data Demonstrating That NC605 Resulted In Enhanced Generation Of Quality Bone With Better Mechanical Properties